FDA Panel Recommends Easing Peptide Manufacturing Restrictions
A U.S. Food and Drug Administration (FDA) advisory committee has recommended lifting restrictions on the manufacture of four peptides for human use. The vote occurred despite ongoing concerns about the peptides' safety and effectiveness.
An expert panel advising the U.S. Food and Drug Administration (FDA) has voted to recommend removing restrictions on the manufacture of four peptides intended for human use. The move, widely anticipated, was made despite a continuing lack of comprehensive evidence regarding the safety and effectiveness of these substances.
The decision follows months of efforts by Health and Human Services Secretary Robert F. Kennedy Jr., a known proponent and user of peptides, to influence the outcome. His involvement has been seen as a key factor in bringing this recommendation forward.
Peptides are chains of amino acids, similar to proteins but generally shorter. They play various roles in the body, often acting as signaling molecules. Some, like insulin, are naturally occurring and crucial for biological processes.
The committee is scheduled to vote on three additional peptides today. The FDA will ultimately make the final decision on whether to change the current regulations.